Skip to main content
OpenTrials
Completed

NCT Number: NCT02303795

RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

RIvaroxaban for Valvular heart diseasE and atRial fibrillation trial (RIVER trial).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Valvular Heart Disease Cardiovascular Diseases Heart Diseases Heart Valve Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Associação do Sanatório Sírio - Hospital do Coração HCor

São Paulo, 04004050, Brazil

About this study

A Phase 2, Randomized, Open label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban compared with vitamin K antagonism in Patients with Atrial Fibrillation with Bioprosthetic Mitral valves - RIVER. Main analysis for the primary endpoint are based on the Restricted Mean Survival Time (RMST) method.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients aged >18 years at time of inclusion
  • Patients with Persistent or paroxysmal Atrial Fibrillation or flutter with bioprosthetic mitral valves.
  • The patient must be able to give informed consent

Exclusion criteria

  • Cardiovascular-related conditions as known presence of cardiac thrombus or tumor
  • Active endocarditis
  • Uncontrolled hypertension
  • Hemorrhage risk-related criteria
  • Active internal bleeding
  • History of, or condition associated with, increased bleeding risk
  • Concomitant conditions and therapies
  • History of previous thromboembolism with high risk of bleeding:
  • Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months
  • Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization
  • Acute MI within the last 14 days prior to randomization
  • Treatment with: Chronic aspirin therapy > 100 mg daily or dual antiplatelet therapy; Intravenous antiplatelets; Fibrinolytics; Anticipated need for long-term treatment with a nonsteroidal antiinflammatory drug; Systemic treatment with a strong inhibitor of cytochrome P450 3A4, such as ketoconazole or protease inhibitors; Treatment with a strong inducer of cytochrome P450 3A4, such as rifampicin, phenytoin, phenobarbital, or carbamazepine.
  • Anemia
  • Pregnancy or breastfeeding or women of reproductive age not using effective contraceptive methods
  • Calculated creatinine clearance bellow 30 mL/min
  • Known significant liver disease or alanine aminotransferase N3× the upper limit of normal
  • Previous participation in this study.

Treatment and study plan

Rivaroxaban

Drug

Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.

Warfarin

Drug

Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.

Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day.

Primary outcomes

  1. Major Clinical Events

    Time frame: 12 months

    Combined Endpoint of major clinical events as defined by strokes (CVA), transient ischemic attack (TIA), major bleeding, all-cause death, valve thrombosis and non-CNS systemic embolism, hospitalization due to cardiac failure.

Secondary outcomes

  1. Major bleeding

    Time frame: 12 months

    Clinically overt bleeding associated with: fatal outcome, involving a critical site, or clinically overt bleeding associated with a fall in hemoglobin concentration of ≥2 g/dL, or leading to transfusion of ≥2 units of packed red blood cells or whole blood.

  2. Combined endpoint of nonfatal stroke (CVA), transient ischemic attack (TIA), systemic embolism, valve thrombosis, venous thromboembolism and vascular causes death.thrombosis, and vascular death

    Time frame: 12 months

    Stroke: sudden, focal neurologic deficit from a presumed cerebrovascular cause, not reversible within 24 hours and not due to na identifiable cause.

    Non-CNS systemic embolism: abrupt vascular insufficiency associated with clinical or radiologic evidence of arterial occlusion.

    Valve thrombosis: any thrombus attached to or near an implanted valve that occludes part of the blood flow, interferes with function or warrant treatment.

    Mortality: Deaths any cause. Venous thromboembolism: verification by definitive diagnostic evaluation. Deep Vein Thrombosis: abnormal compression ultrasound or intraluminal filling defect on venography or autopsy.

    Pulmonary embolism: at least one: 1) intraluminal filling defect on CT scan; 2) intraluminal filling defect on pulmonary angiogram; 3) high- probability on v/p lung scan; 4)inconclusive spiral CT, pulmonary image with demonstration of DVT in the lower extremities; 5) autopsy

Sponsors and collaborators

Lead sponsor

Hospital do Coracao

Other

Registry information

Official study title

A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Dec 1, 2014
Registry last updated
Apr 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.